US2015150841A1PendingUtilityA1

Dronedarone for use in Leishmaniasis, Formulations and Associations for Use in Leishmaniasis

37
Assignee: SANOFI SAPriority: May 22, 2012Filed: May 22, 2013Published: Jun 4, 2015
Est. expiryMay 22, 2032(~5.8 yrs left)· nominal 20-yr term from priority
Inventors:Stephane BeillesSandra ChambonnetJean-Pierre Collaveri
A61P 33/02A61K 31/133A61K 47/36A61K 47/14A61K 31/343A61K 45/06A61K 9/107A61K 9/0014A61K 47/10A61K 9/06A61K 31/7048A61K 31/685A61K 47/38Y02A50/30
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of leishmaniasis, formulations and associations comprising dronedarone or one of its pharmaceutically acceptable salts for the treatment of leishmaniasis.

Claims

exact text as granted — not AI-modified
1 . Dronedarone or one of its pharmaceutically acceptable salts for use in the treatment of leishmaniasis. 
     
     
         2 . Dronedarone for use according to  claim 1  in the treatment of cutaneous leishmaniasis. 
     
     
         3 . Dronedarone for use according to  claim 1  in the treatment of leishmaniasis issued from  Leishmania amazonensis  strains. 
     
     
         4 . Dronedarone for use according to  claim 1  in the treatment of leishmaniasis issued from  Leishmania amazonensis  strains resistant to pentavalent antimonials derivatives. 
     
     
         5 . Dronedarone for use according to  claim 4  wherein said pentavalent antimonials derivative is meglumine antimoniate. 
     
     
         6 . Dronedarone for use according to  claim 1  in the treatment of leishmaniasis issued from  Leishmania donovani  strains. 
     
     
         7 . Dronedarone for use according to  claim 1  in the treatment of leishmaniasis issued from  Leishmania major  strains. 
     
     
         8 . Dronedarone for use according to  claim 1  wherein said pharmaceutically acceptable salt is dronedarone hydrochloride. 
     
     
         9 . Formulation comprising dronedarone or one of its pharmaceutically acceptable salts for topical administration. 
     
     
         10 . Formulation according to  claim 9  wherein said formulation comprises at least a pharmaceutically acceptable excipient 
     
     
         11 . Formulation according to  claim 9  wherein said pharmaceutically acceptable salt is dronedarone hydrochloride. 
     
     
         12 . Formulation according to  claim 9  wherein said formulation is a hydro-alcoholic gel. 
     
     
         13 . Formulation according to  claim 10  wherein said pharmaceutically acceptable excipient is hydroxypropyl methylcellulose. 
     
     
         14 . Formulation according to  claim 9  for use as a medicine. 
     
     
         15 . Formulation according to  claim 9  for use in the treatment of leishmaniasis. 
     
     
         16 . Formulation according to  claim 9  for use in the treatment of cutaneous leishmaniasis. 
     
     
         17 . Formulation according to  claim 9  for use in the treatment of leishmaniasis issued from  Leishmania amazonensis  strains. 
     
     
         18 . Formulation according to  claim 9  for use in the treatment of leishmaniasis issued from  Leishmania amazonensis  strains resistant to pentavalent antimonials derivatives. 
     
     
         19 . Formulation according to  claim 18  wherein said pentavalent antimonials derivative is meglumine antimoniate. 
     
     
         20 . Formulation according to  claim 9  for use in the treatment of leishmaniasis issued from  Leishmania donovani.    
     
     
         21 . Formulation according to  claim 9  for use in the treatment of leishmaniasis issued from  Leishmania major.    
     
     
         22 . Formulation according to  claim 9  wherein dronedarone or one of its pharmaceutically acceptable salt may be used in a proportion of 10% by weight of the active principle in base form. 
     
     
         23 . Association of dronedarone or one of its pharmaceutically acceptable salts and an anti-leischmaniasis agent. 
     
     
         24 . Association according to  claim 23  for use in the treatment of leishmaniasis. 
     
     
         25 . Association according to  claim 23  for use in the treatment of cutaneous leishmaniasis. 
     
     
         26 . Association according to  claim 23  for use in the treatment of leishmaniasis issued from  Leishmania amazonensis  strains. 
     
     
         27 . Association according to  claim 23  for use in the treatment of leishmaniasis issued from  Leishmania amazonensis  strains resistant to pentavalent antimonials derivatives. 
     
     
         28 . Association according to  claim 23  wherein said anti-leischmaniasis agent is selected among the following agents:
 Miltefosine or one of its pharmaceutically acceptable derivatives, 
 Amphotericin B or one of its pharmaceutically acceptable derivatives, 
 pentavalent antimonials derivatives such meglumine antimoniate. 
 
     
     
         29 . Association according to  claim 27  wherein said said pentavalent antimonials derivative is meglumine antimoniate. 
     
     
         30 . Association according to  claim 23  for use in the treatment of leishmaniasis issued from  Leishmania donovani  strains. 
     
     
         31 . Association according to  claim 23  for use in the treatment of leishmaniasis issued from  Leishmania major  strains.

Join the waitlist — get patent alerts

Track US2015150841A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.